Published online before print July 10, 2003, doi: 10.1161/01.STR.0000083051.93319.28
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2003;34:2025.)
© 2003 American Heart Association, Inc.
Original Contributions |
Closure of the Blood-Brain Barrier by Matrix Metalloproteinase Inhibition Reduces rtPA-Mediated Mortality in Cerebral Ischemia With Delayed Reperfusion
From the Departments of Neurology (T.P., G.A.R.), Neurosciences (G.A.R.), and Cell Biology and Physiology (G.A.R.), University of New Mexico Health Sciences Center, Albuquerque, New Mexico.
Correspondence to Thomas Pfefferkorn, MD, Department of Neurology, Klinikum Grosshadern, Ludwig-Maximilians-Universitaet, Marchioninistrasse 15, 81377 Muenchen, Germany. E-mail thomaspfefferkorn{at}hotmail.com
Background and Purpose— Intravenous recombinant tissue plasminogen activator (rtPA) can be beneficial in ischemic stroke despite an increased risk of hemorrhage and potential neurotoxic effects. We hypothesized that rtPA-mediated adverse effects depend on the timing of reperfusion and injury to the blood-brain barrier (BBB).
Methods— Male Wistar rats had middle cerebral artery occlusion (MCAO) by intraluminal thread placement. Intervals of ischemia/reperfusion, respectively, in hours were 0/18, 1.5/16.5, 3/15, 6/12, 18/0, and 6/1. Animals received either rtPA or saline for 1 hour at the time of reperfusion or, for the 18/0 trial, starting 1 hour after MCAO. Outcome parameters were mortality, matrix metalloproteinase-2 and -9 (MMP-2 and -9) concentrations, tissue hemoglobin, and brain water content. We analyzed the permeability of the BBB by using the brain 14C[sucrose] uptake method. Effects of the MMP inhibitor BB-94 on the BBB without rtPA treatment and on mortality with rtPA were tested in animals with 6/1 and 6/12, respectively.
Results— In delayed reperfusion (6/12), rtPA increased mortality from 17% to 83% (P<0.01) without significantly affecting other outcome parameters. In 6/1, sucrose uptake in the ischemic hemisphere was markedly increased (8.80±1.14% vs 2.15±0.26%; P<0.01). This uptake was reduced by treatment with BB-94 (3.95±1.48%, P<0.01). Furthermore, BB-94 reduced rtPA-mediated mortality in 6/12 to 33% (P<0.05).
Conclusions— rtPA-mediated mortality in delayed reperfusion is associated with early opening of the BBB. Closure of the BBB with BB-94 given before rtPA treatment reduced mortality, suggesting that treatment with MMP inhibitors might reduce the risk associated with thrombolysis.
Key Words: blood-brain barrier • metalloproteinases • thrombolysis • rats
This article has been cited by other articles:
 |
|
 |
|
  L. S. Machado, I. Y. Sazonova, A. Kozak, D. C. Wiley, A. B. El-Remessy, A. Ergul, D. C. Hess, J. L. Waller, and S. C. Fagan Minocycline and Tissue-Type Plasminogen Activator for Stroke: Assessment of Interaction Potential Stroke, September 1, 2009; 40(9): 3028 - 3033. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Liu, J. Hendren, X.-J. Qin, and K. J. Liu Normobaric Hyperoxia Reduces the Neurovascular Complications Associated With Delayed Tissue Plasminogen Activator Treatment in a Rat Model of Focal Cerebral Ischemia Stroke, July 1, 2009; 40(7): 2526 - 2531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. H. Liu, Z. You, C.-M. Liu, Y. R. Kim, M. J. Whalen, B. R. Rosen, and P. K. Liu Diffusion-Weighted Magnetic Resonance Imaging Reversal by Gene Knockdown of Matrix Metalloproteinase-9 Activities in Live Animal Brains J. Neurosci., March 18, 2009; 29(11): 3508 - 3517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Strbian, M.-L. Karjalainen-Lindsberg, P. T. Kovanen, T. Tatlisumak, and P. J. Lindsberg Mast Cell Stabilization Reduces Hemorrhage Formation and Mortality After Administration of Thrombolytics in Experimental Ischemic Stroke Circulation, July 24, 2007; 116(4): 411 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ning, K. L. Furie, W. J. Koroshetz, H. Lee, M. Barron, M. Lederer, X. Wang, M. Zhu, A. G. Sorensen, E. H. Lo, et al. Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke Neurology, May 23, 2006; 66(10): 1550 - 1555. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J.T.H. Roelofs, K. M.A. Rouschop, J. C. Leemans, N. Claessen, A. M. de Boer, W. M. Frederiks, H.R. Lijnen, J. J. Weening, and S. Florquin Tissue-Type Plasminogen Activator Modulates Inflammatory Responses and Renal Function in Ischemia Reperfusion Injury J. Am. Soc. Nephrol., January 1, 2006; 17(1): 131 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wang and S. E. Tsirka Neuroprotection by inhibition of matrix metalloproteinases in a mouse model of intracerebral haemorrhage Brain, July 1, 2005; 128(7): 1622 - 1633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rosell, J. Alvarez-Sabin, J. F. Arenillas, A. Rovira, P. Delgado, I. Fernandez-Cadenas, A. Penalba, C. A. Molina, and J. Montaner A Matrix Metalloproteinase Protein Array Reveals a Strong Relation Between MMP-9 and MMP-13 With Diffusion-Weighted Image Lesion Increase in Human Stroke Stroke, July 1, 2005; 36(7): 1415 - 1420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Benchenane, V. Berezowski, C. Ali, M. Fernandez-Monreal, J. P. Lopez-Atalaya, J. Brillault, J. Chuquet, A. Nouvelot, E. T. MacKenzie, G. Bu, et al. Tissue-Type Plasminogen Activator Crosses the Intact Blood-Brain Barrier by Low-Density Lipoprotein Receptor-Related Protein-Mediated Transcytosis Circulation, May 3, 2005; 111(17): 2241 - 2249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Benchenane, V. Berezowski, M. Fernandez-Monreal, J. Brillault, S. Valable, M.-P. Dehouck, R. Cecchelli, D. Vivien, O. Touzani, and C. Ali Oxygen Glucose Deprivation Switches the Transport of tPA Across the Blood-Brain Barrier From an LRP-Dependent to an Increased LRP-Independent Process Stroke, May 1, 2005; 36(5): 1059 - 1064. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Wang, K. Tsuji, S.-R. Lee, M. Ning, K. L. Furie, A. M. Buchan, and E. H. Lo Mechanisms of Hemorrhagic Transformation After Tissue Plasminogen Activator Reperfusion Therapy for Ischemic Stroke Stroke, November 1, 2004; 35(11_suppl_1): 2726 - 2730. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dittmar, G. Kiourkenidis, M. Horn, S. Bollwein, G. Bernhardt, G. A. Rosenberg, and T. Pfefferkorn Cerebral Ischemia, Matrix Metalloproteinases, and TNF-{alpha}: MMP Inhibitors May Act Not Exclusively by Reducing MMP Activity * Response Stroke, July 1, 2004; 35(7): e338 - e340. [Full Text] [PDF]
|
|
|
|
|
|
C. M. Maier, L. Hsieh, F. Yu, P. Bracci, and P. H. Chan Matrix Metalloproteinase-9 and Myeloperoxidase Expression: Quantitative Analysis by Antigen Immunohistochemistry in a Model of Transient Focal Cerebral Ischemia Stroke, May 1, 2004; 35(5): 1169 - 1174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Straub, U. Junghans, V. Jovanovic, H. J. Wittsack, R. J. Seitz, and M. Siebler Systemic Thrombolysis With Recombinant Tissue Plasminogen Activator and Tirofiban in Acute Middle Cerebral Artery Occlusion Stroke, March 1, 2004; 35(3): 705 - 709. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H. Lo, J. P. Broderick, and M. A. Moskowitz tPA and Proteolysis in the Neurovascular Unit Stroke, February 1, 2004; 35(2): 354 - 356. [Full Text] [PDF]
|
|